Hemovent GmbH, an Aachen, Germany-based medical device company, closed a $6m Series A funding.
The round was led by MIG Verwaltungs AG (Munich, Germany) with participation from WCTI Partners (Portland, Ore., USA); Seed Fond Aachen II (Aachen, Germany); KfW Bank (Bonn, Germany); NRW.BANK.Venture Fonds (Duesseldorf, Germany); and, PB Beteiligung- und Vermoegensverwaltung.
Co-founded by Christof Lenz, CEO, Dr. Oliver Marseille, CTO, Hemovent has developed a small self-contained and portable Extra Corporeal Membrane Oxygenation (ECMO) system that supports or replaces heart and lung function in the event of cardiac and respiratory failure.
FinSMEs
10/02/2016